<?xml version="1.0" encoding="UTF-8"?>
<p>Cancer persists to be a major hurdle to human wellbeing causing the second-highest mortality rate after cardiovascular diseases
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. Despite the advances in chemotherapeutic approaches, unmet clinical needs maintain cancer as a leading cause of death
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>. Furthermore, cancer is a group of heterogeneous diseases with multifactorial etiology and inevitability for resistance evolvement. These challenges along with our continuous understanding of oncogenesis suggest that a multitarget single molecule with polypharmacological mechanisms might afford a novel promising chemotherapeutic agent
 <xref rid="CIT0004" ref-type="bibr">
  <sup>4</sup>
 </xref>.
</p>
